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Abstract. We determined the prevalence of IgG antibodies to hepatitis E virus (anti-HEV IgG) among travelers
attending Boston-area travel health clinics from 2009 to 2010. Pre-travel samples were available for 1,356 trav-
elers, with paired pre- and post-travel samples for 450 (33%). Eighty of 1,356 (6%) pre-travel samples were posi-
tive for anti-HEV IgG. Compared with participants who had never lived in nor traveled to a highly endemic
country, the pre-travel prevalence odds ratio (POR) of anti-HEV IgG among participants born in or with a history
of previous travel to a highly endemic country was increased (POR = 4.8, 95% CI = 2.3–10.3 and POR = 2.6,
95% CI = 1.4–5.0, respectively). Among participants with previous travel to a highly endemic country, anti-HEV
IgG was associated with age > 40 years (POR = 3.7, 95% CI = 1.3–10.2) and travel history to ≥ 3 highly endemic
countries (POR = 2.7, 95% CI = 1.2–5.9). Two participants may have contracted HEV infection during their
2009–2010 trip.
INTRODUCTION
Hepatitis E virus (HEV) is a single-strand RNA virus (family
Hepeviridae, genus Orthohepevirus). HEV infection causes
acute hepatitis that is generally self-limited. However, HEV
infection can also lead to liver failure and death in pregnant
women, as well as become chronic in immunocompro-
mised individuals.1,2 There is no commercially available vac-
cine for HEV.
Globally, HEV causes an estimated 20 million infections,
3.3 million acute cases, and 56,600 deaths each year.3 A
portion of infected individuals are asymptomatic.4 HEV
occurs throughout much of the world, but it is highly
endemic in many areas with inadequate sanitation and lim-
ited access to safe drinking water, where it is spread primar-
ily via the fecal-oral route. The prevailing HEV genotypes in
these areas are genotypes 1 and 2.5 In highly endemic areas,
HEV causes waterborne outbreaks involving hundreds to
thousands of cases and accounts for a substantial propor-
tion of sporadic hepatitis infections.6
There have been reports of autochthonous HEV infections,
unrelated to travel, in industrialized countries, including the
United States. Symptomatic HEV infections in low-incidence
countries generally occur among older adults.7 The prevail-
ing HEV genotype in low-incidence countries is genotype 3,
which is frequently isolated from mammals, including swine;
zoonotic transmission is suspected.5 The National Health
and Nutrition Evaluation Survey (NHANES) reported that the
prevalence of IgG antibodies against HEV (anti-HEV IgG)
among the general U.S. population aged ≥ 6 years
declined from 10.2% during 1988–1994 to 6.0% during
2009–2010; the prevalence for those born in the United
States declined from 9.6% to 5.2% over the same period.8
A proportion of individuals with anti-HEV IgG in low-
incidence countries may have been infected with HEV
while living in or traveling to high-incidence countries.
Increased seroprevalence was reported among NHANES
participants born outside of the United States.8,9 Studies
from Spain and Italy have also found that immigrants
from highly endemic countries have a higher prevalence
of anti-HEV IgG compared with the general population.10,11
In a case–control study of blood donors from California,
donors with anti-HEV IgG were more likely than those
without antibodies to report history of travel to highly
endemic areas.12
As HEV infection can have severe consequences for
travelers who are pregnant or immunocompromised, it is
important to identify factors associated with HEV infection.
Although a few studies have examined seroconversion to
antibodies against HEV during travel, the frequency of sero-
conversion and the demographic and travel history factors
associated with pre- and post-travel HEV antibody status
are not well understood.13–15 The Boston Area Travel Medi-
cine Network (BATMN) was a research collaboration of five
travel clinics in the greater Boston area that saw approxi-
mately 7,500 travelers each year in a variety of settings.
From this network, we sought to 1) identify demographic
and travel history predictors of pre-travel anti-HEV IgG
and 2) determine frequency of seroconversion to anti-HEV
IgG during travel.
METHODS
Participants and procedures. Participants were interna-
tional travelers seeking pre-travel health consultations at
BATMN clinics and enrolled in one of two dengue research
studies, for whom serum was available for testing for anti-
HEV IgG. Both research studies had convenience samples
of participants ≥ 2 years old who came to the clinics for
preparation for planned travel to dengue-endemic countries
for at least 2 weeks. The first study was a dengue seroprev-
alence study with an enrollment period of August 2008 to
June 2009.16 Participants enrolled in the seroprevalance
study in November 2008 or later were eligible for testing
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testing for anti-HEV IgG. The second was a dengue sero-
conversion study with an enrollment period of January
2009 to September 2010.17 To be eligible for enrollment
in the seroconversion study, participants must have indi-
cated that they would be available to return for follow-up
after travel.
Each BATMN clinic obtained institutional review board
(IRB) approval for the samples to be tested for dengue and
other viruses. The studies were also reviewed by the Cen-
ters for Disease Control and Prevention (CDC) Human Sub-
jects Advisors, who approved reliance on Boston University
Medical Center’s IRB. We obtained written consent from
participants ≥ 18 years of age, written assent and parental
consent for participants aged 7–17 years, and parental con-
sent for those < 7 years of age.
At the pre-travel consultation, participants were asked
about demographic information, travel history, travel plans,
medical history, and vaccination history. Blood samples
were collected from each participant. At 2–3 months post-
travel, participants enrolled in the seroconversion study
returned to the clinic to provide repeat blood samples and
answer questions regarding their travel. Serum samples
were stored at −70°C for future testing.
Hepatitis E antibody testing. All pre- and post-travel
specimens were de-identified and shipped to the Labora-
tory Branch, Division of Viral Hepatitis, CDC, for anti-HEV
IgG testing, which was performed using a commercially
available enzyme immunoassay (Diagnostic System Ltd.,
DSI S.r.l., Saronno, Italy). Samples that were initially reac-
tive were retested in duplicate for confirmation.
Data analysis. We used published maps that categorize
highly endemic countries as those with either reported
waterborne outbreaks or confirmed HEV infection in at least
25% of sporadic non-A, non-B hepatitis cases.18 To match
the period of data collection, countries were categorized as
highly endemic for HEV using 2010 data (Figure 1). For
analysis, participants were stratified into four groups based
on their level of previous time spent in highly endemic
countries (Table 1). Group 1 included those born in highly
endemic countries. Group 2 included participants who
were not born in highly endemic countries, but who had
lived in a highly endemic country for at least 1 year. Group 3
included participants who had never lived in a highly endemic
country but had a history of travel to at least one highly
endemic country prior to the study. Group 4 included par-
ticipants who had never lived in nor traveled to a highly
endemic country.
Data were entered into a password-protected data-
base (CS Pro, U.S. Census Bureau, Washington, DC).
Analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC). Bivariate and multivariate compari-
sons between proportions were performed using logistic
regression to estimateo prevalence odds ratios (POR)
and Wald 95% confidenceintervals (CIs). Hosmer and
Lemeshow goodness-of-fit tests were performed on mul-
tivariate models. Comparisons between medians were
FIGURE 1. Global distribution of hepatitis E virus infection, 2010.18
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performed using Kruskal–Wallace χ2 tests. A P < 0.05 was
considered to be statistically significant.
RESULTS
HEV antibody test results. Of the 1,356 participants
included in the analysis, 80 (6%) were positive for anti-HEV
IgG before travel (Figure 2). After returning from travel, 450
(33%) of the 1,356 participants were retested. Of 417 ini-
tially negative participants who were retested, two (0.5%)
seroconverted to anti-HEV IgG. Of 33 initially positive par-
ticipants who were retested, anti-HEV IgG became unde-
tectable in one (3%).
Participant characteristics. Of 1,356 participants before
travel, 958 (71%) were born in the United States, 736 (54%)
were female, 913 (67%) were white, and ages ranged from
4 to 83 years (median = 35) (Table 1). There were 152 (11%)
participants in Group 1, 51 (4%) in Group 2, 710 (52%) in
Group 3, and 443 (33%) in Group 4. Participants in Group 4
had a median age of 30 years and were significantly
younger than participants in all other groups: Group 1
(median age = 37, P = 0.001), Group 2 (median age = 39,
P = 0.002), and Group 3 (median age = 41, P < 0.0001).
Pre-travel anti-HEV IgG status. Anti-HEV IgG positivity
status varied by group (Table 2). Compared with partici-
pants in Group 4, of whom 2% had anti-HEV IgG, the prev-
alence odds of anti-HEV IgG was 2.6 (95% CI = 1.4–5.0) for
participants in Group 3, and 4.8 (95% CI = 2.3–10.3) for
participants in Group 1.
Among participants in Group 1, participants born in Africa
had 2.9 times (95% CI = 1.0–8.1) the prevalence odds of
anti-HEV IgG pre-travel in comparison with participants
born in Asia. Among participants in Group 4, participants
older than age 40 had 7.1 times (95% CI = 1.4–35.9) the
prevalence odds of anti-HEV IgG compared with participants
aged 20–40. Sex and race were not significant predictors of
anti-HEV IgG prevalence odds among participants in Group 1,
Group 2, or Group 4.
Among participants in Group 3, history of travel to three
or more highly endemic countries, in comparison with his-
tory of travel to 1–2 highly endemic countries, was associ-
ated with a POR of 2.7 (95% CI = 1.2–5.9) of anti-HEV IgG,
controlling for region of birth, sex, race, and age (Table 3).
Age older than 40 years, compared with age of 20–40 years,
was also significantly associated with anti-HEV IgG (adjusted
POR = 3.7, 95% CI = 1.3–10.2), after controlling for region of
birth, sex, history of travel, and race. On bivariate analysis,
white race, compared with non-white race, was associated a
POR of 5.0 (95% CI = 1.2–21.1), but this association was
not significant in the multivariate analysis.
Among participants in Group 3, anti-HEV IgG was also
significantly associated with median days spent in highly
endemic countries (P = 0.02). These participants who were
positive for anti-HEV IgG had a history of travel in highly
endemic countries for a median of 38 days (range = 7–385),
TABLE 1
Demographics of 1,356 pre-travel participants tested for IgG antibodies against hepatitis E virus by the Boston Area Travel Medicine Network
from November 2008 to September 2010, stratified by level of previous exposure to countries highly endemic for Hepatitis E
Total
Group 1: born in a highly
endemic country
Group 2: not born in a highly endemic
country but lived in one for ≥ 1 year
Group 3: never lived in a highly endemic
country but traveled to at least one
Group 4: never lived in or traveled to
a highly endemic country Overall
152 51 710 443 1,356
Attribute N % N % N % N % N %
Country of birth
United States N/A N/A 42 82 576 81 340 77 958 71
Other 152 100 9 18 117 16 98 22 376 28
Missing 0 0 0 0 17 2 5 1 22 2
Sex
Female 71 47 23 45 381 54 261 59 736 54
Male 80 53 28 55 327 46 180 41 615 45
Missing 1 < 1 0 0 2 < 1 2 < 1 5 < 1
Race
White 6 4 42 82 566 80 299 67 913 67
Non-white 140 92 7 14 116 16 128 29 391 29
Missing 6 4 2 4 28 4 16 4 52 4
Age
< 20 3 2 1 2 17 2 14 3 35 3
20–40 48 32 15 29 209 29 232 52 504 37
> 40 38 25 15 29 227 32 103 23 383 28
Missing 63 41 20 39 257 36 94 21 434 32
N/A = not applicable.
FIGURE 2. Pre- and post-travel hepatitis E IgG antibody results
among 1,356 participants who received pre-travel care at Boston
Area Travel Medicine Network clinics during January 2009 to
September 2010.
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whereas participants who were negative for anti-HEV IgG
had a history of travel in highly endemic countries for a
median of 24 days (range = 1–1,710). Among participants in
Group 1 and Group 2, there was no association between
anti-HEV IgG and time spent in a highly endemic country.
Among participants with history of birth in, travel to, or liv-
ing in highly endemic countries, prevalence of anti-HEV IgG
varied by specific country of exposure (Table 4). Of all highly
endemic countries to which at least 20 participants reported
prior exposure, prevalence was highest for participants who
had been born in, lived in, or traveled to Ethiopia (29%).
Prevalence was lowest for participants who had been born
in, lived in, or traveled to Nepal (5%) or Indonesia (4%).
Among participants in Group 4, history of travel to spe-
cific non-highly endemic countries was associated with
higher prevalence of anti-HEV IgG. Of all countries to which
at least 20 participants in Group 4 reported prior travel,
prevalence was highest for participants who had been to
Peru (10%) and Costa Rica (6%).
Seroconversion to anti-HEV IgG among travelers. Of
the 417 participants with pre-travel negative anti-HEV IgG
results who were retested after travel, 221 (53%) reported
recent travel to at least one highly endemic country. Two
participants, both of whom reported recent travel to at least
one highly endemic country, were positive for anti-HEV IgG
after travel. This represents 1% of all initially negative par-
ticipants retested after returning from a highly endemic
country. No participants reporting travel to countries that
were not highly endemic seroconverted to anti-HEV IgG.
The first participant who likely seroconverted while travel-
ing was an Indian-born 41-year-old female who reported
travel to India and Nepal, where she stayed in hotels and
private homes. The second participant who likely sero-
converted while traveling was a white U.S.-born 60-year-
old female who reported travel to China, where she visited
rural areas, had contact with animals, and stayed at hotels
and hostels. Neither of these participants reported symp-
toms during or after travel.
DISCUSSION
The prevalence of anti-HEV IgG among Boston area indi-
viduals seeking pre-travel consultations at travel clinics was
6%, which is identical to the seroprevalence in the general
U.S. population found by the 2009–2010 NHANES sur-
vey.8,9 Among our study population, only 2.5% of partici-
pants who had never lived in or traveled to a highly
endemic country had anti-HEV IgG. Therefore, it is likely
that some participants were exposed to HEV while living or
traveling outside of the United States.
TABLE 2
Comparison of pre-travel prevalence odds of IgG antibodies against hepatitis E virus (anti-HEV IgG) to exposure history-level grouping among
pre-travel participants evaluated by the Boston Area Travel Medicine Network before travel from January 2009 to September 2010
Hepatitis E exposure level
Anti-HEV IgG (+) pre-travel Anti-HEV IgG (−) pre-travel
Prevalence odds ratio (95% CI)N % N %
Overall (N = 1,356) 80 6 1,276 94 Not applicable
Group 1: born in a highly endemic country (N = 152) 18 12 134 88 4.8 (2.3–10.3)
Group 2: not born in a highly endemic country but lived in a
highly endemic country for at least one year (N = 51)
2 4 49 96 1.5 (0.3–6.7)
Group 3: not born in and never lived in a highly endemic country
but traveled to a highly endemic country (N = 710)
48 7 662 93 2.6 (1.4–5.0)
Group 4: never lived in or traveled to a highly endemic country (N = 443) 12 2 431 97 Referent
CI = confidence interval.
TABLE 3
Characteristics of 710 Boston Area Travel Medicine Network pre-travel participants in Group 3* and seropositivity status for IgG antibodies
against hepatitis E (anti-HEV IgG)
Characteristics
Anti-HEV IgG (+)
(N = 48), N (%)
Anti-HEV IgG (−)
(N = 662), N (%)
Bivariate prevalence
odds ratio (95% CI)
Multivariate prevalence
odds ratio (95% CI)†
Country of birth
United States 38 (79) 538 (81) Referent Referent
Other 10 (21) 124 (19) 1.1 (0.6–2.3) 0.7 (0.2–2.6)
Sex
Male 21 (44) 306 (46) Referent Referent
Female 26 (54) 355 (54) 1.1 (0.6–1.9) 1.2 (0.5–2.5)
Number of highly endemic countries traveled to
1–2 countries 23 (48) 460 (69) Referent Referent
Three or more countries 25 (52) 202 (31) 2.5 (1.4–4.5) 2.7 (1.2–5.9)
Race
Non-white 2 (4) 114 (18) Referent Referent
White 45 (94) 521 (82) 4.9 (1.2–20.6) 3.8 (0.5–30.2)
Age
< 20 years 0 (0) 17 (3) Excluded Excluded
20–40 years 5 (10) 204 (31) Referent Referent
> 40 years 24 (50) 203 (31) 4.8 (1.8–12.) 3.7 (1.3–10.2)
Missing 19 (40) 238 (36) Excluded Excluded
CI = confidence interval.
*Group 3 travelers were not born in, and never lived in, a country highly endemic for hepatitis E but traveled to a highly endemic country.
†Multivariate analysis included 419 participants; participants with missing values for any variable and/or who were younger than 20 years of age at the time of enrollment were excluded.
Hosmer and Lemeshow goodness-of-fit test showed that the model fit well (P = 0.87).
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Factors associated with anti-HEV IgG positivity among
participants with history of travel to but not residence in
highly endemic countries correspond to factors associated
with anti-HEV IgG positivity in the 2009–2010 NHANES.8,9
Among NHANES participants, seroprevalence of anti-HEV
IgG was associated with older age. Similarly, our study
found that age > 40 was associated with increased sero-
prevalence. This could reflect a cohort effect, implying that
incidence of HEV infection was higher in the past.9 It could
also reflect a cumulative effect of exposures over time.
White race was also associated with increased seropreva-
lence of anti-HEV IgG in both our bivariate analysis and
NHANES. The reasons for this are less clear. Other vari-
ables collected by NHANES suggest that affluence may be
associated with increased anti-HEV IgG seroprevalence
among the U.S. population.8 However, we did not assess
affluence in our study population.
Our study found a low incidence of seroconversion to
anti-HEV IgG and no symptomatic HEV infection, which is
consistent with the literature. Of three existing prospective
seroconversion studies of travelers, two reported no sero-
conversion among more than 1,100 Dutch travelers and
84 young Israeli travelers, respectively.13,14 The third reported
four asymptomatic HEV infections among 211 U.S. trav-
elers.15 Discrepancies between study results may be
explained by both laboratory methods used and epidemiol-
ogy of HEV infection in the study populations. Although
symptomatic HEV infection in travelers has not been found
in any existing prospective studies, sporadic cases of
symptomatic HEV infections following international travel
have been described in four U.S. travelers and two travelers
from the United Kingdom.19,20 A study of 154 U.S. patients
with clinical samples negative for hepatitis A and B IgM
found that 26, including 11 with a history of recent travel,
tested positive for anti-HEV IgM.21
The results of this study are subject to a few limitations.
The map provided in Figure 1 categorizes a number of coun-
tries as “not endemic or endemicity unknown.” Because HEV
is present in much of the world, it is likely that most of
these countries have varying levels of HEV endemicity but
data about HEV incidence or outbreaks are not yet avail-
able.3 We did not include countries in this category as
highly endemic countries. This may have led to an underes-
timate of the effect of previous travel to, or birth in, a highly
endemic country. Also, a substantial proportion of partici-
pants were missing values for age. This limited our ability to
draw conclusions about the effect of age and led to a limited
number of participants included in the multivariate analysis.
Further, the investigation was limited to travelers to
dengue-endemic countries, which restricted our under-
standing about travelers to other areas. Because the partic-
ipants in our study were individuals seeking pre-travel care
at travel clinics in the Boston area, they do not represent
the general traveling population of the United States.
In conclusion, previous time spent in highly endemic coun-
tries, as well as other demographic factors, affects seroprev-
alence of hepatitis E among travelers. Our results indicate a
need for better data about HEV transmission and epidemiol-
ogy in common travel destinations for which HEV endemicity
is unknown. In our study, anti-HEV IgG seroconversion dur-
ing travel was rare but present. Although we did not have
any symptomatic infections in our study population, HEV
infection can cause serious illness and is especially danger-
ous for high-risk groups such as pregnant women and
immunocompromised travelers. It is important to address the
risk of acquiring HEV infection during travel and emphasize
preventative measures, such as hand hygiene and safe food
and water practices, during pre-travel consultations, particu-
larly with travelers who are pregnant or immunocompro-
mised. In addition, HEV infection should be considered in the
differential diagnosis for any returning traveler with signs and
symptoms of viral hepatitis.
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